California firm takes cannabinoid research personally

by Invesbrain Tuesday, July 18, 2017
Print This Article

California firm looks to Israel for personalized cannabinoid approach

The news magazine ISRAEL21c reports a U.S. biopharma company is teaming up with an Israeli counterpart to forward the use of cannabinoids in the field of personalized medicine.

California-based CURE Pharmaceutical recently signed a memorandum of understanding with Therapix Biosciences of Tel Aviv. The “research collaboration” will be done in conjunction with the eight hospitals and medical centres of Israel’s Assuta Medical Centers.

Therapix’s lead compound THX-TS01 is currently in phase 2 clinical trials to treat Tourette’s syndrome. It hopes to begin a Phase 1 clinical trial for another compound, THX-ULD01, for the treatment of mild cognitive impairment.

Both compounds employ an “FDA-approved synthetic THC.”

Therapix is also developing new cannabinoid delivery technologies including nasal and sublingual (under the tongue) methods.

(READ MORE)

CMAJ commentary argues for two-stream cannabis system

Arguing ‘recreational cannabis and cannabinoid-based drugs (including medical cannabis) are not equivalent,’ the authors of a commentary in the Canadian Medical Association Journal say Canada should continue with a separate medical cannabis stream after legalization.

In a report by EurekAlert!, Elizabeth Cairns and Dr. Melanie Kelly of Dalhousie University’s Department of Pharmacology, write that “(without) a program that supports medical use, patients may lose access to treatments that the Federal Court of Canada has deemed appropriate, which fosters safe and appropriate use."

The Task Force on Cannabis Legalization and Regulation also recommended a two-streamed system.
According to the EurekAlert! report, “the authors suggest that a medical stream for cannabis and cannabinoids would reduce risk to patients, provide incentives for research into the therapeutic effects of cannabinoids, and provide educational resources for health care practitioners on the latest advances in cannabinoid research.”

(READ MORE)

U.S.-German-Israeli deal links cancer diagnostics with cannabinoids

MMJ Reporter writes an American cannabinoid firm with an R&D foothold in Israel is teaming up with a German “world pioneer in cancer diagnostics.”

Cannabics Pharmaceuticals Inc. recently agreed to become “the exclusive international provider unit” of SIMFO GmbH’s Circulating Tumour Cell (CTC) diagnostics to people suffering with cancer and being treated with CBDs.

SIMFO previously initiated preclinical trials into CBDs and drug development with Cannabics’ cannabinoid formulations.

Cannabics’ R&D facility is “concentrated” in Israel.

(READ MORE)

Data on CBD analogue to be presented at neuroscience meeting

Stockhouse reports Califonia-based NEMUS Bioscience is set to present research on its CBD analogue at the Annual Meeting of the Society of Neuroscience this November.

The data, compiled by NEMUS’ R&D partner the University of Mississippi “will show the superiority of the NEMUS proprietary analogue of CBD, NB2222, versus plant-derived CBD in ameliorating pain in a validated mouse (murine) model of chemotherapy-induced peripheral neuropathy using an opioid as an active comparator.”

The firm will also present data on the anti-addictive potential of NB2222.

"We have been able to demonstrate that NB2222 was able to deliver analgesia comparable to morphine, which has been implicated in the current global opioid abuse epidemic. The research team then moved to the next step using a validated animal model of addiction to opioids to assess the anti-abuse potential of NB2222 as a therapeutic. We look forward to presenting the data this fall," said Dr. Kenneth Sufka, research professor with the National Center for Natural Products Research at UM.

(READ MORE)

Gabriella’s Kitchen Appoints Natural Foods and Packaged Goods Expert Jamie Fay as President & COO

CALGARY and SANTA ROSA, CA, Jan. 21, 2019 /CNW/ – Gabriella’s Kitchen Inc. (“GABY” or the “Company”) (CSE: GABY), an innovative and leading-edge cannabis wellness company, is pleased to announce the appointment of Jamie Fay as President & COO of GABY. Jamie is the fo...

Buy Trulieve Cannabis for a big return: Beacon Securities

Expect a catalyst-rich first half of 2019 for Trulieve Cannabis Corp (Trulieve Cannabis Corp Stock Quote, Chart CSE:TRUL), according to analyst Russell Stanley of Beacon Securities, who on Monday launched coverage of TRUL with a “Buy” recommendation and C$28.00 target price,...

Preparing pension investments for an annuity purchase

Many defined benefit plans’ funded statuses are in relatively good territory, but with an uncertain investment atmosphere on the horizon, is now a good time ......

The Environmental Impact of Cannabis Cultivation

As conscious consumerism enters the cannabis world, purchasing decisions may be based more on fair trade and regenerative farming than on orange hairs and THC percentage. With legalization taking hold, the industry has shifted from trying to protect people from the police to try...

50 top Canadian stock picks for 2019 as chosen by the pros

Last year was a rough one for investors, with markets turning in their worst performance in 10 years. And volatility promises to be a constant challenge for investors in 2019. But where there is upheaval there is also opportunity, and the drop in valuations means there are poten...

Tech Talk for Monday January 21st 2019

  WALL STREET RAW RADIO WITH YOUR HOST, MARK LEIBOVIT SATURDAY, JANUARY 19, 1019 SPECIAL GUESTS: DON VIALOUX, HARRY BOXER, HENRY WEINGARTEN AND SINCLAIR NOE https://tinyurl.com/yb5328r9   Excerpts from Don Vialoux’ comments on Wall Street Raw The bear market rally in North...

Why Concentrates should be made in Labs and Not at Home

When a supply source runs out, that doesn’t mean the demand does. If other options exist, people will sway from their normal routine to fulfill it. It is clear cannabis’ trends will follow suit in more than one way. This includes edibles, as well as the very supply of cannab...

Canopy Growth and Cronos Group will “dominate” the global market, CIBC says

Canadian banks are getting behind cannabis, with the latest effort coming from CIBC, which Thursday launched coverage of the sector, issuing “Outperform” ratings to industry heavyweights Canopy Growth Corp. (Canopy Growth Stock Quote, Chart TSX:WEED, NYSE:CGC) and Cronos Gro...

New Reports on Cannabis & Teenage Brains Overstate the Evidence

Over the past few weeks, most notably after the publication of Alex Berenson’s “Tell Your Children,” the media has been full of successive stories on the supposed mental health hazards of cannabis — seeming to signal a backlash to recent gains in normalizing the plant an...

Weekend Market Roundup 2019-01-19 When Bulls Run Over Everything

Bulls are in charge Breadth is excellent Looks like an initiation thrust Oil buy signal Asia buy signal FOMO - Fear of missing out is starting to kick in for institutional investors This has been a wonderful run for investors. Since the Santa Claus low, the market h...